Individuals who receive surgical aortic valve replacement (SAVR) within three months of an ischemic stroke are almost 15 times more likely to suffer another stroke than SAVR patients without previous strokes, according to a Danish registry study published April 25 in JAMA Cardiology.

A randomized trial published April 24 in JAMA suggests patients with lower-extremity peripheral artery disease (PAD) can’t be expected to improve walking performance on their own, even with the aid of wearable activity trackers and telephone coaching sessions.

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy company using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced first patient enrollment into the pivotal U.S. REFRESH 2-AKI trial.

Intravenous nicorandil cut the risk of periprocedural myocardial injury (pMI) after percutaneous coronary intervention (PCI) by 49 percent among patients 65 and older, according to a substudy of a randomized trial published in PLOS One.

Nearly one in 10 patients who receive percutaneous coronary intervention (PCI) end up back in the hospital with an unplanned readmission within 30 days, according to a study published online April 2 in JACC: Cardiovascular Interventions. These readmissions are usually for noncardiac causes and heavily linked to a patient’s comorbidities and place of discharge, the researchers found.

A hybrid revascularization approach combining PCI and coronary artery bypass grafting (CABG) produced similar five-year outcomes compared to CABG alone, according to a randomized trial of patients with multivessel coronary artery disease (CAD) published in JACC: Cardiovascular Interventions.

Santa Clara, Calif. — April 5, 2018 — Cardiva Medical®, an innovator in the field of vascular closure, today announced the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of the VASCADE® Vascular Closure System. Already approved for use in arterial closure, VASCADE is now FDA approved for use in 5-7F femoral venous closures as well.

DUBLIN — April 9, 2018 — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension).